VickySanzMoreno

Delighted to have been elected a Fellow of the European Academy of Cancer Sciences alongside some outstanding colleagues!
www.europeancanceracademy.eu/news/new-eac...

Applications now open for CRUK Clinical Academic PhD Training Programme. Join us @icr.ac.uk and The Royal Marsden NHS Foundation Trust.
We are offering a super exciting project to investigate cytoskeletal dynamics in Circulating Tumour Cells from Breast Cancer Patients.

Heads up! Small change to Friday’s workshop: Dr. Sebastian Carotta can’t make it, but we’re thrilled to have Dr. Victoria Sanz-Moreno (ICR) stepping in to talk about “Biomechanical hallmarks & vulnerabilities of metastatic & therapy resistant cancer cells” See you there! @vickysanzmoreno.bsky.social

Sad to see three of our beloved lab members leaving us! Yumiko Teigen, Paramita Kundu and Jaume Barcelo- We wish you the best of luck for your future endeavours!
@icr.ac.uk

Early stages of #metastasis are poorly understood despite causing 90% of cancer deaths. A new project led by Prof Darryl Overby and Prof @vickysanzmoreno.bsky.social is looking to develop tools to study #cancer spread in unprecedented detail while reducing the need for animals in research.🐁👇

Targeting AMPK as a metabolic vulnerability of metastatic cancer cells Targeting AMPK as a metabolic vulnerability of metastatic cancer cells

We are offering a super exciting project to develop new ways of targeting metastatic cancer cells!
Amazing supervisory team:
Primary supervisor: Professor Joanna Loizou
Associate supervisor: Professor Zoran Rankovic
Secondary supervisor: Professor Victoria Sanz-Moreno
@icr.ac.uk

We are so happy to welcome @dorioliveri.bsky.social as a new lab member to the Cytoskeleton and Metastasis Team. Doriana will study how the extracellular matrix in different metastatic sites regulates tumour-immune cell interactions😀
ADAPTMET
@icr.ac.uk
@breastcancernow.bsky.social

The stage is set! @vickysanzmoreno.bsky.social is kicking off their keynote at #cellmech2025.

CellMech2025!! Exciting!

Congratulations! Great work👏🏻👏🏻

Congratulations to Yumiko Teigen who had her PhD viva yesterday! She did such a fantastic job! Thanks to the examiners for their insightful comments
@cancerresearchuk.org @breastcancernow.bsky.social @icr.ac.uk @qmbci.bsky.social 😍

Really exciting to see these results from our Curestarter researchers - thanks for sharing @vickysanzmoreno.bsky.social!

Congratulations to Samantha George in the lab for receiving the Best Talk Prize at "The Diversity in Immunology Meeting" by @britsocimm.bsky.social for her beautiful work on tumour-associated macrophages. We are very proud of you Sam! 🤩

Special thanks to dream team spearheaded by Vittoria Graziani and Eva Crosas-Molist; all co-authors and collaborators. Thanks to all the funders that supported us and @cp-cellreports.bsky.social for such a constructive review process!

5. Targeting SLC7A11 offers a therapeutic opportunity for patients with SLC7A11-high tumours. SLC7A11 could also serve as a biomarker for invasive phenotypes, aiding patient stratification and precision oncology approaches.

4. Erastin-mediated SLC7A11 inhibition induced ferroptosis in amoeboid cancer cells. Spheroid invasive growth was markedly suppressed by Erastin but restored upon GSH supplementation, highlighting the protective role of GSH against oxidative stress.

3. Glutathione (GSH) supplementation supported amoeboid cancer cell features decreasing Reactive Oxygen Species caused by SLC7A11 loss. SLC7A11 and GSH maintained redox homeostasis. Metastatic amoeboid cancer cells could not cope with oxidative stress when SLC7A11 was inhibited.

2. Inspecting melanoma biopsies, we found that SLC7A11 protein levels are higher in metastatic lesions vs. primary tumours but also increased at the invasive front. This supports SLC7A11 upregulation as an adaptive feature of aggressive melanoma cells.

🔬 Key findings from our work:

1. SLC7A11 levels are higher in cancer cells with higher Myosin II activity and located at the invasive front of melanomas. SLC7A11 depletion in these cells reduced Myosin II activity and 3D invasion, highlighting its potential role in melanoma dissemination.

SLC7A11 protects amoeboid-disseminating cancer cells from oxidative stress Graziani et al. show that SLC7A11 increases during melanoma disease progression. SLC7A11 promotes Myosin II-driven amoeboid invasive behavior while shielding amoeboid cancer cells from oxidative stres...

🚨 New publication alert! Excited to share our latest work
SLC7A11 protects amoeboid-disseminating cancer cells from oxidative stress: Cell Reports www.cell.com/cell-reports...

The results, published in @cp-cellreports.bsky.social could lead to new tests to spot the most aggressive cancers, and treatments to stop them spreading.

“If we take away the melanoma cells’ shield and armour, we could stop cancer in its tracks.’
- Lead researcher Prof @vickysanzmoreno.bsky.social

BREAKING 📰

A ‘suit of armour’ protein could be targeted to stop aggressive #Melanoma from spreading.

ICR scientists have discovered that SLC7A11 protects the most aggressive melanoma cancer cells from damage as they pass through stressful environments.

More here ⤵️
www.icr.ac.uk/about-us/icr...

I am happy to be shortlisted in the Life Sciences category of the #GlobalCall25. This recognition brings
me a step closer to the Science Breakthroughs of the Year, to be celebrated at the #FallingWalls
#ScienceSummit25 from 6-9 November.
More info: falling-walls.com/science-summ... @FallingWalls

Group photo

A huge thank you to all the amazing delegates who joined us for Small G Proteins in Cellular Signalling and Disease 2025 this week! We hope you enjoyed the conference and look forward to seeing you at the next one. #BiochemEvent #SGP25 🧪

Last day of the #SmallGproteins meeting, great evening last night meeting researchers in the field hearing about people’s journeys, and gave advice on expressing a phosphorylated GTPase.

Looking forward to Session 6 kicked off by @vickysanzmoreno.bsky.social!

@biochemsoc.bsky.social #BiochemEvent

Excited to be selected as one of the Social Media Contributors at the #BiochemEvent Small G Proteins Meeting next week, thanks to @biochemsoc.bsky.social.
I look forward to hearing about and discussing the latest research in the area as well as presenting my own PhD work about Arf proteins!

Group photo from the Mechanometabolism Unleashed: The Interface of Cell Mechanics and Metabolism Workshop Held at Buxted Park, East Sussex, UK 22-25 June 2025

The Company of Biologists Workshop - Mechanometabolism Unleashed: The Interface of Cell Mechanics and Metabolism

Thank you to Workshop organisers Marco Foiani, Ana-Maria Lennon-Duménil, Victoria Sanz-Moreno and Giorgio Scita.

#Workshop #Biology #CellBiology #Community #Collaboration #Research

We are delighted to host @vickysanzmoreno.bsky.social today from the @icr.ac.uk!

"Biomechanical hallmarks and vulnerabilities of metastatic cancer cells"

📍 Alfred Denny Conference Room
📅 4th June - 1pm

@insigneoinstitute.bsky.social
@sheffielduni.bsky.social
@sheffielduni.bsky.social

Very proud of former PhD student Yaiza Jung who has received the #BACR Chris Marshall Prize for Cell Signalling 😍!
it was such a pleasure to co-supervise her PhD with @jezcarlton.bsky.social 😀

ASCO 2025: head and neck cancer immunotherapy and targeted drugs for breast cancer improve outcomes - Cancer Research UK - Cancer News Our experts are helping us sort through the cancer studies at ASCO, the world's biggest cancer conference.

Immunotherapy can help people with advanced head and neck cancer live years longer without their disease growing or coming back. It's the biggest improvement in treating this cancer type for decades.

Find out more: news.cancerresearchuk.org/2025/05/31/asc